ANAVEX2-73
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
4
Sites
60
Countries
6
Endpoints
20
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 20 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 7 of 20 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
2
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ATTENTION-ADOLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | ANAVEX2-73 Alzheimer’s disease | Study partner/caregiver required | Ph 2/3 | Completed | 51 | Jun 2024 | 1 | |
| NCT04575259OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 | ANAVEX2-73 Lewy body dementia | Parkinson's disease dementia | Ph 2 | Completed | 10 | May 2022 | - | |
| NCT02756858An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease | ANAVEX2-73 Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 5 | Nov 2020 | 1 | |
| ANAVEXPhase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease | ANAVEX2-73 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 5 | Nov 2015 | - |
Showing 1-4 of 4 trials